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Abstract
Aims/hypothesis The sodium–glucose cotransporter 2 (SGLT2) inhibitor canagliflozin slows progression of kidney function
decline in type 2 diabetes. The aim of this study was to assess the effect of the SGLT2 inhibitor canagliflozin on biomarkers for
progression of diabetic kidney disease (DKD).
Methods A canagliflozin mechanism of action (MoA) network model was constructed based on an in vitro transcriptomics
experiment in human proximal tubular cells and molecular features linked to SGLT2 inhibitors from scientific literature. This
model was mapped onto an established DKD network model that describes molecular processes associated with DKD.
Overlapping areas in both networks were subsequently used to select candidate biomarkers that change with canagliflozin
therapy. These biomarkers were measured in 296 stored plasma samples from a previously reported 2 year clinical trial com-
paring canagliflozin with glimepiride.
Results Forty-four proteins present in the canagliflozin MoA molecular model overlapped with proteins in the DKD network
model. These proteins were considered candidates for monitoring impact of canagliflozin on DKD pathophysiology. For ten of
these proteins, scientific evidence was available suggesting that they are involved in DKD progression. Of these, compared with
glimepiride, canagliflozin 300 mg/day decreased plasma levels of TNF receptor 1 (TNFR1; 9.2%; p < 0.001), IL-6 (26.6%; p =
0.010), matrix metalloproteinase 7 (MMP7; 24.9%; p = 0.011) and fibronectin 1 (FN1; 14.9%; p = 0.055) during 2 years of
follow-up.
Conclusions/interpretation The observed reduction in TNFR1, IL-6, MMP7 and FN1 suggests that canagliflozin contributes to
reversing molecular processes related to inflammation, extracellular matrix turnover and fibrosis.
Trial registration ClinicalTrials.gov NCT00968812
Keywords Biomarkers . Canagliflozin . Chronic kidney disease . Sodium–glucose cotransporter 2 inhibitors . Type 2 diabetes
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Abbreviations
CANTATA-SU Canagliflozin Treatment and Trial
Analysis-Sulfonylurea
CCL C-C motif chemokine ligand
CKD Chronic kidney disease
DKD Diabetic kidney disease
FABP Fatty acid binding protein
FN1 Fibronectin 1
HGF Hepatocyte growth factor
HIF1A Hypoxia-inducible factor 1α
MCP-1 Monocyte chemoattractant protein 1
MMP Matrix metalloproteinase
MoA Mechanism of action
SGLT2 Sodium–glucose cotransporter 2
TNFR1 TNF receptor 1
UACR Urinary albumin/creatinine ratio
VEGFA Vascular endothelial growth factor A
Introduction
Chronic kidney disease (CKD) is present in 35–40% of indi-
viduals with type 2 diabetes. These individuals are at marked-
ly increased risk of end-stage kidney disease, cardiovascular
disease and premature mortality compared with individuals
without CKD despite optimal recommended treatment [1].
Novel treatments are therefore highly desired to mitigate the
high residual risk [2].
Sodium–glucose cotransporter 2 (SGLT2) inhibitors are a
relatively new class of oral glucose-lowering drugs. They in-
hibit the SGLT2 transporter in the S1 segment of the proximal
tubule in the kidney and cause glycosuria and natriuresis.
Previous studies have shown that SGLT2 inhibitors improve
several cardiovascular and renal risk factors including HbA1c,
BP, body weight and albuminuria [3, 4]. Results from large
cardiovascular outcome trials demonstrated that these beneficial
effects translate into cardiovascular protection and delay of kid-
ney function decline [5, 6]. The exact mechanisms by which
SGLT2 inhibitors reduce the risk of cardiovascular and kidney
disease are not completely understood but are thought to in-
volve natriuresis, restoration of tubuloglomerular feedback
and amelioration of intrarenal hypoxia [7]. In addition, experi-
mental studies have suggested possible anti-inflammatory and
antifibrotic effects for SGLT2 inhibitors [8, 9].
Advancements in omics technologies coupled with high-
dimensional data integration via systems medicine approaches
can provide new insights into the molecular mechanism of
action (MoA) of drugs and pathways of disease progression
[10]. In a recent study, we used publicly available and exper-
imental data to develop a molecular process model of diabetic
kidney disease (DKD) [11]. Themodel was subsequently used
to derive and validate novel biomarkers predicting progres-
sion of DKD. The current study expands this work and uses
a similar bioinformatics approach to construct a molecular
MoA network model describing the impact of the SGLT2
inhibitor canagliflozin at a molecular level. Biomarker candi-
dates for monitoring the efficacy of canagliflozin in slowing
the progression of CKD in individuals with type 2 diabetes
were selected based on network interference of the
canagliflozin MoA and DKD pathophysiological process
model. The candidate biomarkers were then validated in plas-
ma samples from the Canagliflozin Treatment and Trial
Analysis-Sulfonylurea (CANTATA-SU) trial, a phase 3 clini-
cal trial comparing canagliflozin with glimepiride [12].
Methods
The overall analysis workflow from in silico modelling to
biomarker validation in clinical trial samples is depicted in
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Fig. 1. In brief, network-based molecular models were gener-
ated using omics data and literature-extracted information for
DKD as well as the effects of canagliflozin reflecting disease
pathophysiology and drugMoA. Subsequently, network inter-
ference analysis of the two molecular models was performed.
This analysis formed the basis for the selection of biomarkers
which were subsequently measured in samples from the
CANTATA-SU clinical trial (ClinicalTrial.gov registration
no. NCT00968812) in order to determine the effects of
canagliflozin on these biomarkers.
Cell culture experiments and gene expression analysis
Proximal tubular human kidney cells (HK2) were purchased
from American Type Culture Collection (CRL-2190; Wesel,
Germany) and cultured in keratinocyte serum-free medium
(KSFM) containing 10% FBS, 5 ng/ml recombinant EGF
(rEGF), 0.05 mg/ml bovine pituitary extract (BPE), 100 U/ml
penicillin and 100 μg/ml streptomycin. Cell culture supplies
were purchased from ThermoFisher Scientific, Vienna,
Austria. All cells were grown at 37°C in a humidified atmo-
sphere with 5% CO2. After growth to confluency, cells were
deprived of serum for 24 h. Thereafter, cells were either treated
with 0.5 μmol/l canagliflozin (Biozol, Eching, Germany) or
left untreated, and subsequently the canagliflozin-treated or
untreated cells were stimulated with high glucose (30 mmol/
l; Sigma-Aldrich, Vienna, Austria). The chosen canagliflozin
concentration lay between the calculated IC50 (half maximal
inhibitory concentration) and Cmax (peak plasma concentra-
tion) based on prior work [13, 14]. The glucose concentration
was also selected on the basis of prior studies [15, 16]. After a
total of 24 h, RNAwas isolatedwith RNeasyMini Kit (Qiagen,
Valencia, CA, USA) according to the manufacturer’s protocol.
RNA yield and quality were determined using a DS-11 FX+
spectrophotometer (DeNovix, Wilmington, DE, USA).
Agilent Whole Human Genome Microarrays 4.44 v2
(Agilent Technologies, Santa Clara, CA, USA) were used
for gene expression profiling with four biological replicates
in the treatment as well as in the control arm. Samples were
randomized and blinded before analysis. All materials for mi-
croarrays were purchased from Agilent Technologies, USA.
For each sample, 200 ng total RNA was used. Cyanine 3
(Cy3)-labelled complementary RNA (cRNA) was generated
with the Low Input QuickAmp Labeling Kit (5190-2305) for
hybridisation to oligonucleotide microarrays (Human GE
4x44K v2, G4845A). Arrays were scanned at 5 μm using an
Axon Gene Pix 4000B scanner (Molecular Devices,
Sunnyvale, CA, USA) and signal intensity data were extracted
using Agilent Feature Extraction software (v.9.5.3.1).
Pre-processing of transcriptomics data, including back-








in the CANTATA-SU study
Fig. 1 Study analysis overview
scheme. Molecular models were
generated based on literature-
derived data as well as in vitro-
derived transcriptomics profiles
for DKD and canagliflozin.





Biomarkers in areas of network
interference were selected and
validated in samples from the
completed CANTATA-SU
clinical trial
1156 Diabetologia (2019) 62:1154–1166
of identical sequence probes, was done using the R package
Agi4x44preprocess. The 17,985 probes remaining in the anal-
ysis set were annotated with the most up-to-date annotation
file (026652_D_AA_20150612.txt) downloaded from
Agilent’s array webpage (www.chem.agilent.com/cag/bsp/
gene_lists.asp) on 25 August 2015. Isolated statistical
significance testing provides a large set of features with
minor effective fold changes, a frequent finding in in vitro
settings. As this hampers the interpretation of biological
relevance, we used in addition a fold change criterion
(>|1.2|) to identify transcripts of eventual relevance,
which were successively mapped to their respective
protein-coding gene in the Ensembl Gene IDs namespace.
Microarray data were deposited at the Gene Expression
Omnibus (https://www.ncbi.nlm.nih.gov/geo) and are
available under reference number GSE106156.
Molecular model generation and network interference analy-
sis The construction of the DKD molecular model was based
on a set of molecular features extracted from scientific articles
with a focus on diabetic nephropathy. Publications annotated
with the major MeSH term ‘diabetic nephropathies’ were ex-
tracted in January 2016 and genes/markers were derived from
these research articles using the National Center for
Biotechnology Information (NCBI)’s gene2pubmed mapping
file downloaded on 7 April 2015 from ftp://ftp.ncbi.nlm.nih.
gov/gene/DATA/. Extracted molecular features were mapped
to their corresponding Ensembl Gene ID and further mapped
onto a hybrid protein interaction network that consists of
protein-coding genes (nodes) and protein–protein interaction
data from IntAct, BioGRID and Reactome combined with
computationally inferred relations and interactions between
members (edges) [17]. Subsequently, the DKD gene set and
the respective interactions were extracted if the molecular fea-
tures (nodes) shared at least one interaction with one other
member. This DKD interaction model was used for subse-
quent interference analysis with an in silico-generated
canagliflozin MoA molecular model.
The canagliflozin MoA molecular model was constructed
on the basis of extraction of molecular features from scientific
literature complemented by molecular features deregulated
after canagliflozin treatment from the in-house in vitro exper-
iment on human proximal tubular cells. Molecular features
extracted from scientific literature consisted of those reported
to be affected by high glucose in the proximal tubule and those
reported to be targeted by SGLT2 inhibition. Molecular fea-
tures affected by high glucose in proximal tubule cells were
extracted from a review article by Vallon [18]. Molecular fea-
tures targeted by SGLT2 inhibition were extracted from pub-
lications focusing on one of the following approved or exper-
imental SGLT2 inhibitors: canagliflozin, dapagliflozin,
empagliflozin, ipragliflozin, tofogliflozin, remogliflozin,
sergliflozin, ertugliflozin and T-1095. Extracted molecular
features were mapped to their respective Ensembl Gene IDs
and further mapped on the hybrid protein interaction network.
The resulting subgraph connecting the canagliflozin-
associated molecular features was extended by addition of
molecular features showing deregulation after canagliflozin
treatment by at least 1.2-fold as compared with untreated cells
in the in vitro setting and being linked to at least one of the
literature-associated molecular features also showing deregu-
lation at the transcriptional level.
Areas in the DKD molecular model affected by
canagliflozin treatment were identified by network interfer-
ence analysis. In other words, shared molecular features as
well as shared protein–protein interactions were identified be-
tween the DKD molecular model and the canagliflozin MoA
molecular model. These areas in the network were subse-
quently used to identify biomarker candidates that could be
changed with canagliflozin therapy and be used to monitor
canagliflozin response.
Candidate biomarker selection Interfering nodes forming part
of the DKDmolecular model as well as the canagliflozinMoA
molecular model were evaluated as biomarker candidates.
Scientific publications linked to the respective molecular fea-
tures via gene2pubmed and annotated with the major MeSH
term ‘diabetic nephropathies’ and the MeSH terms ‘biological
markers’ and ‘prognosis’ were retrieved. Publications were
further filtered for being annotated with the MeSH terms
‘humans’ or ‘disease models, animal’ or reporting results from
a clinical trial. We excluded high-throughput omics profiling
studies. This set of prognostic markers for which at least one
publication discussed the respective marker in the context of
DKD prognosis was complemented by prognostic biomarkers
as described in our previous work [11]. Next to the prognostic
factors that were also part of the canagliflozin MoAmolecular
model, we also prioritised prognostic biomarkers located in
close network proximity to areas of molecular model interfer-
ence as these biomarkers are mechanistically linked to
canagliflozin MoA. The prioritised biomarkers were subse-
quently measured in plasma samples to evaluate whether their
concentration changed during treatment with canagliflozin.
Clinical study design and population The candidate bio-
markers were subsequently assessed in plasma samples from
all participants with type 2 diabetes mellitus and a urinary
albumin/creatinine ratio (UACR) >1.7 mg/mmol who took
part in the randomised, double-blind, active-controlled
CANTATA-SU trial (NCT00968812). The design and main
outcomes of this trial were previously reported [19]. This trial
was originally designed to assess the effect of canagliflozin
100 mg/day, canagliflozin 300 mg/day or glimepiride titrated
to 6–8 mg/day based on the maximum approved dose in the
country of the investigational site. Individuals with a UACR
>1.7 mg/mmol were selected to enrich the population for
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those at higher risk of renal function decline [19]. The
CANTATA-SU trial consisted of a 2 week, single-blind, pla-
cebo run-in period, a 52 week, double-blind core treatment
period and a 52 week pre-specified double-blind extension
treatment period during which participants continued their
originally assigned treatment. Eligible participants were be-
tween 18 and 80 years of age and had type 2 diabetes, with
an HbA1c between 53mmol/mol and 80mmol/mol (7.0% and
9.5%) while receiving metformin ≥2000 mg/day (or
≥1500 mg/day if higher doses were not tolerated). The trial
was done in accordance with the Declaration of Helsinki and
Good Clinical Practice guidelines. Ethics committees and in-
stitutional review boards approved the research protocol. All
participants provided written informed consent before any
study-specific procedure commenced.
Biomarker measurement UACR was measured using first
morning void urine samples collected at the time of
randomisation and after 52 and 104 weeks. Serum creatinine
and HbA1c levels were measured in fresh samples at baseline
and at weeks 4, 12, 18 (HbA1c only), 26, 36, 44, 52, 64, 78, 88
and 104. Serum creatinine was used to calculate eGFR with
the Modification of Diet in Renal Disease equation [20].
Plasma samples for future biomarker assays were collected
at the time of randomisation, at week 52 and at week 104
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Fig. 2 CanagliflozinMoAmodel construction. The literature-basedMoA
core model was constructed based on molecular features extracted from
publications on SGLT2 inhibitors as well as from a manuscript on the
impact of hyperglycaemia on tubulus cells [18]. The MoA core model
(consisting of 74 connected protein-coding genes out of the set of 78) was
expanded by deregulated transcripts from the in vitro cell culture exper-
iment in HK2 cells, thus leading to the final canagliflozinMoAmolecular
model holding 105 protein-coding genes. Up- and downregulated pro-
tein-coding genes after canagliflozin treatment in HK2 cells are highlight-
ed in red and green, respectively, in the final canagliflozin MoA molec-
ular model. The intensity of colour indicates the level of up- and down-
regulation, with darker colours representing the greatest change. Cana,
canagliflozin; CTRL, control; HG, high glucose; TX, transcriptomics.
MGEA5 is also known as OGA
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were sent to the central laboratory of the University Medical
Center Groningen. Biomarkers selected through the systems
biology approach were measured using a standard
multiplexed Luminex technology. Luminex multiplex assays
(ThermoFisher Scientific, Vienna, Austria) were used as they
enabled measurement of multiple biomarker simultaneously
in small amounts of plasma. The coefficient of variation, as
determined in our own laboratory for the measured bio-
markers, ranged between 1.8% (hepatocyte growth factor)
and 8.8% (IL-6). All measurements were performed using a
Luminex 200 machine (Bio-Rad, Hercules, CA, USA) with
xPONENT software version 4.2 Build 1324 (www.
luminexcorp.com/download/xponent-software-version/),
according to the manufacturer’s instructions.
Statistics Differences in percentage changes in biomarker
levels between randomised groups during follow-up were es-
timated from mixed repeated measures model (MRMM). The
model included treatment, visit and treatment-by-visit interac-
tion as factors and baseline biomarker level as a covariate. All
biomarkers except fibronectin 1 (FN1) were log-transformed
before entering in the MRMM to alleviate the skewness of the
data. Visits were included as repeated measure units from the
same individual. To allow generality for the covariance struc-
ture for the repeated measures, an unstructured variance–
covariance matrix was used. In the MRMMmodel, all partic-
ipants and all data points were included. A contrast statement
was used to test the difference in the percentage biomarker
change between each canagliflozin group vs glimepiride. To
determine which biomarkers could be used to monitor the
effect of canagliflozin on changes in kidney function during
104 weeks of follow-up, we used the week 52 values, since
that was the first time point at which biomarkers were mea-
sured and effects of canagliflozin were considered to be fully
present after 52 weeks. We first determined Pearson correla-
tions between changes in biomarkers and UACR at week 52.
Subsequently, biomarkers that significantly changed during
canagliflozin treatment were selected to determine the associ-
ation between the changes in these biomarkers from baseline
to week 52 and eGFR decline during 104 weeks of follow-up.
An MMRM model was used for this purpose. The model
included treatment and visit as factors and biomarker change
and biomarker change-by-visit interaction as covariates. The
model was adjusted for baseline age, sex, systolic and diastol-
ic BP, BMI, HbA1c, eGFR, albuminuria and change in albu-
minuria from baseline to week 52. A p value <0.05 (two-
sided) was considered to indicate a statistically significant
difference. Correlation analysis between biomarkers and
UACR was performed in R version 3.4.1 (https://cran.r-
project.org/bin/windows/base/) using the Pearson correlation
coefficient and setting the significance value to <0.001. Other
analyses were performed using SAS 9.3 for Windows (SAS
Institute, Cary, NC, USA).
Results
Selection of biomarker candidates for monitoring and
predicting canagliflozin response Figure 1 shows the overall
workflow. The DKD pathophysiology process model includ-
ed 593 molecular features associated with DKD based on
scientific literature that were interlinked at the protein–
protein interaction level and thus considered for further anal-
yses. The constructed canagliflozinMoAmolecular model, on
the other hand, consisted of 105 unique molecular features.
The literature-based canagliflozin MoA core model consisted
of 74 molecular features. Eleven of these were deregulated at
the gene expression level in the in vitro gene expression study.
The canagliflozin core MoA model was extended by an addi-
tional set of 31 differentially expressed genes that were linked
to the deregulated genes in the core model (Fig. 2).
Network alignment analysis identified 44 proteins in the
DKD molecular model that were also part of the canagliflozin
MoA molecular model, thus forming the network interference
signature as shown in Fig. 3. These proteins were considered
candidates serving as proxy for monitoring the impact of
canagliflozin on pathophysiological mechanisms of DKD.





Fig. 3 DKD–drug interference signature and selected biomarkers. The 44
protein-coding genes of the DKD–drug interference signature are shown
along with genes encoding the three prognostic factors, MMP7, MMP8
and TNFR1, tightly connected to the interference signature. Protein-cod-
ing genes are grouped based on mechanistic involvement and molecular
function. The ten biomarkers selected for measurements with Luminex
technology in the CANTATA-SU study are highlighted in red. CTGF is
also known as CCN2; TNFR1 is also known as TNFRSF1A
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discussing the respective molecular feature in the context of
DKD progression. The following markers were measurable
with a multiplexed Luminex assay: IL-6, C-C motif chemo-
kine ligand (CCL) 5 (also known as regulated on activation,
normal Tcell expressed and secreted [RANTES]), CCL2 (also
known asmonocyte chemoattractant protein 1 [MCP-1]), fatty
acid binding protein 1 (FABP1), vascular endothelial growth
factor A (VEGFA) and hepatocyte growth factor (HGF). This
set was complemented by prognostic DKD markers being in
close network proximity to areas of interference in the DKD
and canagliflozin MoA molecular model and also measurable
with Luminex technology, namely TNF receptor superfamily
member 1A (TNFRSF1A), better known as TNF receptor
1 (TNFR1), as well as matrix metalloproteinase (MMP)7
and MMP8. FN1 completed the panel of selected measur-
able markers that were part of both generated molecular
models together with evidence of them being a mechanis-
tic marker for DKD and having prognostic potential re-
garding cardiovascular events.
Biomarker changes during canagliflozin treatment A total of
296 out of the 1452 participants in the CANTATA-SU trial
with UACR ≥1.7 mg/mmol and stored plasma samples were
selected for analysis (Fig. 4). The baseline characteristics of
the population are shown in Table 1. Mean (±SD) eGFR in the
overall population was 89.9 ± 18 ml min−1 [1.73 m]−2 and
median (25th–75th percentile) UACR was 3.7 [2.3–7.0] mg/
mmol. HbA1c levels were similar at baseline and throughout
follow-up among the three treatment groups. As previously
presented, reductions in HbA1c during follow-up among treat-
ment groups were similar. The characteristics of the included
population in comparison with the overall clinical trial popu-
lation are shown in electronic supplementary materials (ESM)
Table 1.
During 104 weeks of follow-up, TNFR1, IL-6, MMP7,
FN1 and HGF levels increased in the glimepiride-treated
group (Fig. 5). Compared with glimepiride, treatment with
canagliflozin attenuated these increases or even significantly
decreased the levels of these biomarkers (Fig. 5 and Table 2).
Table 1 Baseline characteristics






Age, years 56.4 ± 8 56.8 ± 10 55.6 ± 9
Female sex 34 (38.2) 47 (44.3) 46 (45.5)
Systolic BP, mmHg 135.3 ± 12 134.9 ± 13 130.8 ± 14
Diastolic BP, mmHg 81.4 ± 9 80.9 ± 8 80.6 ± 7
BMI, kg/m2 31.7 ± 5 29.9 ± 5 30.6 ± 5
HbA1c, mmol/mol 63.5 ± 9 63.6 ± 9 62.1 ± 8
HbA1c, % 8.0 ± 0.8 8.0 ± 0.8 7.8 ± 0.8
eGFR, ml min−1 [1.73 m]−2 87.4 ± 15 89.7 ± 20 92.2 ± 18
UACRa, mg/mmol 4.1 (2.6–8.3) 3.8 (2.2–6.9) 3.0 (2.3–6.4)




n=2 did not take 
study drug
n=483 assigned to 
canagliflozin 100 mg/day
n=485 assigned to 
canagliflozin 300 mg/day
n=96 discontinued n=88 discontinued n=105 discontinued
n=386 completed n=395 completed n=380 completed






n=482 assigned to 
glimepiride
Fig. 4 Trial profile and patient
disposition of the randomized
controlled trial CANTATU-SU
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Compared with glimepiride, canagliflozin 100 mg and
300 mg decreased albuminuria over 104 weeks by 12.7%
(95% CI −8.3, 29.7%; p = 0.214) and 35.7% (95% CI 20.1,
48.3; p < 0.001), respectively. Biomarker changes or achieved
biomarker levels in the overall population and during
canagliflozin 300 mg treatment at 52 and 104 weeks did not
correlate, or only modestly correlated, with albuminuria
changes or achieved albuminuria levels at both time points
(Fig. 6 and ESMFig. 1). Additionally, generally weak positive
correlations were noted among biomarkers both at week 52
and week 104 (Fig. 6 and ESM Fig. 1).
A further analysis evaluated whether biomarker changes
can be used to monitor the treatment effect of canagliflozin.






















































































































































Fig. 5 Change in biomarkers during glimepiride and canagliflozin treat-
ment. Red squares/lines, glimepiride; light blue circles/lines,
canagliflozin 100 mg/day; dark blue triangles/lines, canagliflozin
300 mg/day. Least square mean (LSM) changes are provided on each
graph. Data are presented as mean ± 95% CI. n = 296 for all markers.
*p ≤ 0.05, canagliflozin vs glimepiride
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changes from baseline to week 52, the earliest available time
point, and eGFR change over 104 weeks of follow-up. TNFR1
was the only biomarker for which the change was significantly
associated with decline in eGFR (p = 0.026 when modelled as
a continuous variable), independent of other risk markers of
kidney function decline. Changes in other biomarkers were not
associated with eGFR decline. When the change in TNFR1
was stratified in tertiles, least square mean eGFR change was
−0.6 (95%CI −2.5, 1.3), −4.8 (95%CI −6.6, −3.0) and −7.6
(95%CI −9.5, −5.8) ml min−1 [1.73 m]−2 in increasing TNFR1
tertiles (Fig. 7a). Similar results were obtained when the pop-
ulation was stratified according to change in TNFR1: reduction
≥30%; between 30% and 0%; and >0% increase (Fig. 7b).
Discussion
In this study we used a systems biology approach to select
biomarkers for how the SGLT2 inhibitor canagliflozin may
slow progression of DKD. Biomarkers at the interference of
DKD pathophysiology and canagliflozin MoA included pro-
teins associated with inflammatory processes, extracellular
matrix deregulation and fibrosis. In a clinical trial setting,
canagliflozin treatment indeed decreased TNFR1, IL-6,
MMP7 and FN1 levels compared with glimepiride treatment,
suggesting that canagliflozin treatment contributes to the re-
versal of molecular processes related to inflammation, extra-
cellular matrix and fibrosis.
SGLT2 inhibitors appear to exert profound protective ef-
fects on kidney function in individuals with type 2 diabetes.
The underlying mechanisms responsible for this beneficial
effect are thought to be related to improvements in renal oxy-
genation and reducing intraglomerular hypertension and
hyperfiltration. The present study suggests that, in addition
to these effects, SGLT2 inhibition with canagliflozin exerts
anti-inflammatory and antifibrotic effects and protects against
extracellular matrix deregulation. These findings are in line
with experimental studies demonstrating that in kidney tissues
of animals treated with SGLT2 inhibitors markers of inflam-
mation and fibrosis, including NF-κB, CCL2 and IL-6 de-
creased [8, 9].
The biomarkers, selected through the systems biology ap-
proach and changed during canagliflozin treatment, have been
associated with progressive kidney function loss in other stud-
ies. Inflammation involving TNF-α has emerged as a key
determinant of DKD progression. Binding of TNF to its re-
ceptor TNFR1 at the podocyte in the kidney stimulates cyto-
kine production and inflammation. Bound TNFR1 can be
shed by cleaving enzymes and is released in the extracellular
space including the blood circulation. Various studies have
consistently shown that circulating TNFR1 predicts risk of
end-stage kidney disease in individuals with type 1 and type
2 diabetes [21–24]. These studies focused on a single TNFR1
measurement as predictor of risk for adverse kidney out-
comes. Prior studies did not, however, evaluate whether inter-
ventions decrease high TNFR1 levels or whether the reduction
in TNFR1 associates with reduced risk of adverse kidney out-
comes. To our knowledge only one other drug apart from
canagliflozin, namely the Janus kinase 1 (JAK1)–signal trans-
ducer and activator of transcription 2 (STAT2) inhibitor
baricitinib, has been shown to decrease TNFR1 levels in in-
dividuals with type 2 diabetes [25]. However, whether reduc-
tions in TNFR1 after baricitinib treatment were associated
with reduced eGFR decline could not be determined due to
the short follow-up of the respective study. This study reveals
for the first time that reductions in TNFR1 levels are indepen-
dently associated with a lesser degree of kidney function de-
cline. This suggests that TNFR1 is not only a strong risk
marker but may even be a target for treatment.
IL-6 is another important inflammatory mediator that is
targeted by canagliflozin. Triggered by hyperglycaemia, the
release of IL-6 in podocytes, mesangial cells and tubule cells
contributes to and sustains local and systemic subclinical in-
flammation [26]. Genetic studies have linked IL6 gene
Table 2 Least squares mean per-
centage difference between
canagliflozin 100 mg and 300 mg
vs glimepiride
Marker Canagliflozin 100 mg vs glimepiride p value Canagliflozin 300 mg vs glimepiride p value
TNFR1 −5.9 (−10.3, 1.3) 0.013 −9.2 (−13.5, −4.7) <0.001
IL-6 −26.3 (−41.7, −6.9) 0.011 −26.6 (−42.0, −7.2) 0.010
MMP7 −16.3 (−32.7, 4.2) 0.11 −24.9 (−39.8, −6.4) 0.011
MMP8 7.4 (−7.8, 25.1) 0.36 15.5 (−1.0, 34.8) 0.07
FN1 −15.8 (−30.9, −0.7) 0.040 −14.9 (−30.1, 0.4) 0.055
CCL2 0.8 (−7.7, 10.2) 0.85 −0.3 (−8.9, 9.1) 0.95
CCL5 13.8 (−7.3, 39.6) 0.22 9.6 (−10.9, 34.8) 0.38
HGF −7.3 (−16.2, 2.6) 0.14 −6.4 (−15.6, 3.7) 0.20
VEGFA 0.0 (−12.7, 14.8) 0.99 −7.1 (−19.1, 6.7) 0.30
FABP1 −2.4 (−20.0, 19.1) 0.97 −2.0 (−30.8, 38.6) 0.81
Data are presented as mean (95% CI)
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polymorphisms with progression of kidney function decline,
highlighting the important role of IL-6 in kidney disease [27].
MMPs are involved in collagen metabolism and are asso-
ciated with fibrotic processes in the kidney. Previous studies
showed that circulating levels of MMPs, including MMP7,
are elevated in individuals with DKD and correlate with renal
function [28, 29]. Interestingly, our in vitro tubular cell exper-
iment showed that hypoxia-inducible factor 1α (HIF1A) was
an essential feature of the DKD pathophysiology model and
the canagliflozin MoA model. Intrarenal hypoxia is typically
observed in diabetic kidneys and improvements in intrarenal
oxygen tension during SGLT2 inhibition may in part account
for the protective effects of SGLT2 inhibitors, as reviewed
elsewhere [30]. Future studies using urine samples are needed
to validate HIF1A as a candidate marker for monitoring re-
sponse to canagliflozin treatment.
We previously developed a network-based molecular inter-
action model of DKD to identify biomarkers associated with
kidney disease progression [11]. The model accounts for the
complex interplay between the different molecular processes
involved and reflects the complex pathophysiology of DKD.
Model-derived biomarker panels significantly added to pre-
diction of kidney function decline in individuals at early and
advanced stages of DKD [11]. In the current study, an updated
DKD molecular model was used and a network-based MoA
molecular model for canagliflozin was developed using a
Fig. 6 Correlation (Pearson’s r) between changes in albuminuria and
selected biomarkers during canagliflozin treatment. (a) Correlation be-
tween changes in biomarkers from baseline to week 52 in the overall
population. (b) Correlation between changes in biomarkers from baseline
to week 52 in the canagliflozin 300 mg treatment group. (c) Correlation
between achieved biomarker levels at week 52 in the overall population.
(d) Correlation between achieved biomarker levels at week 52 in the
canagliflozin 300 mg treatment group. Red shading, statistically signifi-
cant positive correlations; green shading, statistically significant negative
correlations
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similar bioinformatics analysis approach. Subsequent network
interference analysis identified deregulated pathophysiologi-
cal DKD processes potentially affected by canagliflozin treat-
ment. This interference signature enabled an MoA-based bio-
marker identification for validation in a clinical trial setting.
Our approach has the advantage of increasing the probability
of success by incorporating pathway and process information
in the selection procedure.
There are also limitations to our approach. We acknowl-
edge that not all selected biomarkers changed during
canagliflozin therapy, indicating that there is room for im-
provement regarding our network-based selection strategy.
In the current network alignment analysis we used undirected
biological networks and solely focused on the co-occurrence
of protein nodes. Accounting for detailed information on net-
work edges and weighing them either based on literature co-
occurrence or co-expression in renal tissue might be an ap-
proach to focusing on critical paths within the network. The
inclusion of graph measures to estimate node importance,
such as degree or betweenness centrality, might add additional
information on the most relevant nodes supporting marker
selection. Another reason why certain selected markers did
not show positive results, however, might be that measure-
ments in the current study were restricted to plasma samples.
Plasma biomarker levels are thought to reflect systemic pro-
cesses and do not always specifically reflect kidney involve-
ment. Unfortunately, urine samples from participants of the
clinical trial were not used. As an example, we did not observe
a reduction in CCL2 plasma levels during canagliflozin treat-
ment in this study. It is possible that plasma CCL2 levels do
not accurately reflect intrarenal CCL2 levels and that urinary
CCL2 may provide a better reflection of intrarenal CCL2
levels. However, in another study of 31 patients with type 2
diabetes and high albuminuria treated with the SGLT2 inhib-
itor dapagliflozin, we observed a reduction in urinary CCL2
levels [31]. EGF is another interesting molecular marker re-
ported to be associated with renal pathophysiology and pro-
gression of eGFR decline [32]. Based on molecular model
interference analysis, EGF was also among the marker candi-
dates of interest but was not selected for further analysis be-
cause EGF does not qualify for measurements in plasma sam-
ples with the Luminex technology. Connective tissue growth
factor and MMP2 were also identified as promising bio-
markers of canagliflozin response based onmodel interference
but they could not be measured with the Luminex technology
either. Another limitation is that we determined the effects of
canagliflozin in individuals with elevated albuminuria to en-
rich the population at higher risk of kidney function decline.
This may have affected the generalisability of the results to the
broader population of individuals with type 2 diabetes who
have lower levels of albuminuria. Finally, the clinical trial
assessed the effect of canagliflozin against an active control,
glimepiride. This has the advantage that glycaemic control
among the treatment arms was similar. The effects on bio-
markers are thus unlikely to be explained by the modest dif-
ferential effects on glycaemic control and suggest that
canagliflozin has anti-inflammatory and antifibrotic effects
independent of its effect on glycaemic control. However, the
lack of a placebo arm means that no definitive conclusion can
be drawn on whether canagliflozin improves the biomarker
levels or glimepiride worsens the biomarker levels. Thus, vali-
dation of the current set of biomarkers in larger trials in DKD,
such as the Canagliflozin and Renal Endpoints in Diabetes with
Established Nephropathy Clinical Evaluation (CREDENCE)
trial, is required to foster the clinical implementation of these
biomarkers [33].
In conclusion, this study shows that canagliflozin treatment
decreases the plasma concentration of TNFR1, IL-6, MMP7
and FN1 in individuals with type 2 diabetes and elevated
albuminuria. These data suggest that canagliflozin contributes
to reversing molecular processes related to inflammation, ex-
tracellular matrix and fibrosis.
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